Our top pick for
Building a portfolio
Seagen Inc is a biotechnology business based in the US. Seagen shares (SGEN) are listed on the NASDAQ and all prices are listed in US Dollars. Seagen employs 2,092 staff and has a trailing 12-month revenue of around USD$2.2 billion.
|52-week range||USD$117.91 - USD$213.94|
|50-day moving average||USD$147.9457|
|200-day moving average||USD$173.6586|
|Wall St. target price||USD$192.06|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$3.37|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Seagen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Seagen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Seagen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 43x. In other words, Seagen shares trade at around 43x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Seagen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$649.2 million.
The EBITDA is a measure of a Seagen's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$2.2 billion|
|Operating margin TTM||27.44%|
|Gross profit TTM||USD$1.1 billion|
|Return on assets TTM||12.02%|
|Return on equity TTM||22.88%|
|Market capitalisation||USD$26.1 billion|
TTM: trailing 12 months
There are currently 2.5 million Seagen shares held short by investors – that's known as Seagen's "short interest". This figure is 18.7% down from 3.1 million last month.
There are a few different ways that this level of interest in shorting Seagen shares can be evaluated.
Seagen's "short interest ratio" (SIR) is the quantity of Seagen shares currently shorted divided by the average quantity of Seagen shares traded daily (recently around 1.2 million). Seagen's SIR currently stands at 2.13. In other words for every 100,000 Seagen shares traded daily on the market, roughly 2130 shares are currently held short.
However Seagen's short interest can also be evaluated against the total number of Seagen shares, or, against the total number of tradable Seagen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Seagen's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Seagen shares in existence, roughly 10 shares are currently held short) or 0.0407% of the tradable shares (for every 100,000 tradable Seagen shares, roughly 41 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Seagen.
Find out more about how you can short Seagen stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Seagen.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 29.88
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Seagen's overall score of 29.88 (as at 12/31/2018) is nothing to write home about – landing it in it in the 56th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Seagen is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 1.18/100
Seagen's environmental score of 1.18 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Seagen is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 23.34/100
Seagen's social score of 23.34 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Seagen is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 10.36/100
Seagen's governance score puts it squarely in the 5th percentile of companies rated in the same sector. That could suggest that Seagen is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
|Total ESG score||29.88|
|Total ESG percentile||55.9|
|Environmental score percentile||5|
|Social score percentile||5|
|Governance score percentile||5|
We're not expecting Seagen to pay a dividend over the next 12 months.
Over the last 12 months, Seagen's shares have ranged in value from as little as $117.91 up to $213.94. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Seagen's is 0.8792. This would suggest that Seagen's shares are less volatile than average (for this exchange).
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; and Merck. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZIONL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.